BOLT adds Prana's INSPIRE platform and PRA-216 to its inflammation pipeline
BOLT's deal for Prana brings the INSPIRE antibody platform and PRA-216 into a four-indication inflammation pipeline, backed by a $120 million placement.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, the purchase of Prana gives BOLT the INSPIRE multispecific antibody technology and PRA-216, which is already in Phase 2. Both assets feed into a development program covering four inflammatory conditions. To finance the work, the company is raising $120 million through a private placement, and warrants could add up to $60 million more. Management expects this capital to cover spending until 2028, while Phase 2 readouts for PRA-216 are planned for 2027.
why it matters
For biotech investors, the deal combines an early-stage multi-indication pipeline with a funding runway that stretches into 2028, so the 2027 data readouts become the key milestone to watch. The impact on broader markets is limited.
tags
instruments
sources
- BOLT: Prana’s INSPIRE pipeline joins a $120 million-funded push for PRA-216 Phase 2 readouts in 2027 — TradingView, 23 October 2026 at 13:38 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗